Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
HighlightsCreative Biolabs stands at the forefront of therapeutic antibody discovery, leveraging over two decades of expertise to offer our state-of-the-art Phage Display based MemDX™ Human Antibody Discovery Service. This cutting-edge platform uniquely combines the physiological antibody maturation within humanized mice with the unparalleled screening power of phage display immune library technology. The result is a robust and efficient engine for identifying high-affinity, fully human monoclonal antibodies with superior therapeutic potential and reduced immunogenicity risk.
Traditional antibody discovery methods often face a trade-off between natural affinity maturation and the breadth of library screening. Hybridoma technology, while generating antibodies with in vivo matured affinity, can be limited by the number of B cells that can be immortalized. Conversely, synthetic phage display libraries, while vast, may lack the nuances of physiological selection against complex antigens.
Creative Biolabs' MemDX™ human antibody discovery platform bridges this gap. By immunizing our proprietary humanized mice, we allow for a natural immune response and affinity maturation process to occur in a physiological context. The resulting B-cell repertoire, rich with high-affinity antibody candidates, is then captured and immortalized as a phage display immune library. This approach ensures that the antibodies we discover are not only fully human but have also undergone a stringent in vivo selection process, leading to candidates with enhanced specificity, potency, and developability.
Fig. 1 BCR structure.1
Our comprehensive service is designed to be a seamless extension of your research, providing end-to-end support from antigen design to the delivery of fully characterized antibody leads.
Phase 1: Antigen Design and Production
Phase 2: Humanized Mouse Immunization and Monitoring
Phase 3: Phage Display Immune Library Construction and Screening
Phase 4: Antibody Candidate Identification and Characterization
The high-quality, fully human antibodies discovered through our MemDX™ platform are ideal for a wide range of research and therapeutic applications:
Creative Biolabs is your one-stop solution for all antibody development needs. In addition to our flagship humanization service, we offer a full suite of related services to accelerate your program:
Elevate your antibody discovery program with Creative Biolabs' Phage Display based MemDX™ Human Antibody Discovery Service. Contact us today to discuss your project with one of our experts and receive a customized proposal. Let us partner with you to accelerate your journey from target to therapeutic.
Q: What is the primary advantage of using the Phage Display based MemDX™ platform over other human antibody discovery methods?
A: The MemDX™ platform offers a unique dual advantage by synergizing the physiological power of an in vivo immune response with the high-throughput capacity of in vitro phage display. By immunizing humanized mice, we allow for natural B-cell selection and affinity maturation to occur within a living system, resulting in antibodies with superior affinity, specificity, and developability characteristics. We then capture this entire high-quality repertoire in a phage display library of immense diversity (up to 10^11 clones). This integrated approach overcomes the limitations of purely synthetic libraries, which lack in vivo maturation, and traditional hybridoma, which is often limited in throughput and can miss rare B-cell clones. The result is direct access to a broad pool of potent, fully human antibodies optimized by nature and efficiently selected by technology.
Q: What makes an antibody "fully human" and why is this important for therapeutics?
A: A "fully human" antibody is one where the entire protein sequence, including both the variable (Fab) and constant (Fc) regions, is derived from human immunoglobulin genes. This is crucial for therapeutic development because the human immune system is less likely to recognize such an antibody as foreign. Using fully human antibodies, like those generated from our humanized mice, significantly minimizes the risk of an anti-drug antibody (ADA) response in patients. An ADA response can lead to reduced efficacy, altered pharmacokinetics, and potentially severe adverse events. Therefore, starting with a fully human antibody streamlines the path to the clinic by inherently reducing immunogenicity concerns.
Q: What types of antigens are suitable for this service? Can you work with difficult targets like GPCRs?
A: The MemDX™ platform is highly versatile and has been successfully used for a wide array of antigen types, including:
We have proprietary strategies and extensive experience in handling challenging targets like GPCRs, often utilizing whole-cell or virus-like particle (VLP) immunization strategies to present the protein in its native conformational state, which is critical for generating functional antibodies.
Q: Can Creative Biolabs assist if my antigen is difficult to produce?
A: Absolutely. Creative Biolabs provides a full spectrum of molecular biology services. Our team can take your project from the very beginning, starting with gene synthesis and vector construction, followed by protein expression in various systems (bacterial, yeast, insect, or mammalian) and purification. We will work closely with you to design and produce a high-quality antigen suitable for immunization, ensuring the best possible start for your antibody discovery campaign.
Q: How does this service differ from your Single B Cell Antibody Discovery platform?
A: Both platforms aim to deliver high-quality antibodies derived from an in vivo immune response. The primary difference lies in the discovery technology.
The choice between platforms depends on the project goals. Phage display is exceptionally powerful for finding rare binders from a massive pool, while single B cell screening is ideal for speed and recovering natural cognate pairs. Our experts can help you decide which platform is best suited for your specific target and research objectives.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
